Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting

• Status: Withdrawn
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, observational study evaluating the effect of olanzapine for the treatment of refractory chronic nausea and vomiting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• 18-65 years of age

• Able to communicate in English without aid of interpreter

• Have chronic refractory nausea, meeting each of the following criteria:

1. Baseline nausea and vomiting score on VAS of 25mm or greater

2. Duration symptoms of at least 6 months (does not have to be contiguous)

3. Intolerance to or inadequate response to prior treatment with both 1) ondansetron or another serotonin (5HT3) antagonist and 2) metoclopramide or domperidone

Exclusion Criteria:

• History of chemotherapy within the last year

• Current diagnosis of cancer

• Pregnant or breastfeeding

• For females, active efforts to conceive/become pregnant during the time of the study

• Chronic opioid use (3 times a week or greater use)

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation of greater than 2x upper limit of normal (within 3 months of enrollment)

• Cirrhosis

• Unable or unwilling to stop using metoclopramide while using olanzapine

• Concomitant use of other antipsychotics (e.g., haloperidol)

• Prolonged corrected QT interval (QTc) (>470ms for men and >480ms for women)

• History of life-threatening arrhythmia

• Hypokalemia (potassium <3.1) or hypomagnesemia (magnesium <1.2)

• Metabolic syndrome, defined as per Adult Treatment Panel III criteria

• Granulocytopenia (absolute neutrophil count <1500)

• History of tardive dyskinesia

• History of acute dystonic reaction to medications

• History of neuroleptic malignant syndrome